Business Wire

WIPRO

10.3.2021 15:32:07 CET | Business Wire | Pressemeddelelse

Del
Wipro udnævner Pierre Bruno til administrerende direktør for Europa, styrker engagementet i regionen

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), en førende global virksomhed inden for informationsteknologi, konsulentvirksomhed og forretningsprocesser annoncerede i dag udnævnelsen af Pierre Bruno som administrerende direktør, Europa.

I denne rolle vil Bruno lede Wipro’s forretning i seks forskellige regioner på tværs af Europa. Denne udnævnelse, er en dristig indikation af virksomhedens fortsatte investering og fokus på det europæiske marked, som bygger på Wipros fremdrift i hele regionen i de seneste år.

“Pierre har mere end 25 års erfaring inden for IT-infrastruktur, konsulent og servicesektoren. Han har leder virksomheder i både hypervækstmiljøer og inden for teknologi transformation. Med hans erfaring i ledelse af store teams er han godt positioneret til at føre Wipros vækstrejse videre i Europa,” sagde Thierry Delaporte, CEO & MD, Wipro Limited.

“Jeg er begejstret for muligheden for at lede Wipro’s aktiviteter på det europæiske marked, der byder på fantastiske muligheder for vækst. Jeg ser frem til at videreudvikle samt fremme vores engagement over for vores europæiske kunder, når de navigerer i deres forretningstransformation og fortsætter med at udvikle sig i en digital verden,” sagde Pierre Bruno , Administrerende direktør, Europa .

Bruno kommer til Wipro fra DXC Technology, hvor han var vicepræsident og administrerende direktør for Sydeuropa, ansvarlig for alle dele af forretningen, herunder rådgivning, integration, apps, cloud og cybersikkerhed. Bruno arbejdede også for Dell i 14 år i flere roller i Asien, Stillehavsområdet, Japan og EMEA. Han spillede en central rolle i Dells transformation fra at sælge hardware til at blive en vigtig aktør inden for levering af infrastrukturløsninger.

Bruno har en kandidatgrad i forretningsadministration (MBA) med hovedfag i Marketing og økonometri fra HEC Graduate School i Paris. Han har også en kandidatgrad i bioteknik.

Wipro’s forpligtelse i Europa
Wipro’s europæiske tilstedeværelse omfatter seks regioner, bestående af Storbritannien og Irland, Tyskland, Schweiz, Norden, Benelux og Sydeuropa, samt tre near-shore leverancecentre og omfatter en bred vifte af betydelige kunder på tværs af brancher, hvoraf mange bliver supporteret af Wipro på deres teknologiste vækst samt transformationsrejse..

Nogle af de seneste aftaler i Europa omfatter

  • En vigtig strategisk digital og IT-partnerskabsaftale med METRO AG, en førende global grossistvirksomhed.
  • Et engagement med den Finland-baserede producent af ren energi Fortum for at hjælpe med at opgradere applikationslandskabet samt tilhørende serviceintegration,.
  • En flerårig global aftale om automotive engineering services med den italienske bilgigant Marelli.
  • I Tyskland arbejder vi sammen med Telefónica Germany/O2 og dets bredere økosystem til at transformere deres forretningssupportsystemer og tilhørende kvalitetssikring for at sikre en optimal kundeoplevelse og vækst i B2B-markedssegmentet.
  • En strategisk, flerårig infrastruktur’s modernisering og digital transformations services fra det tyskbaserede energiselskab E.ON.

Om Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) er en førende global virksomhed inden for informationsteknologi, rådgivning og forretningsprocesser. Vi udnytter styrken af kognitive computing, hyper-automatisering, robotteknologi, cloud , analytics og nye teknologier til at hjælpe vores kunder med at tilpasse sig den digitale verden og gøre successfulde. En virksomhed, der er anerkendt globalt for sin omfattende portefølje af services, stærkt engagement i bæredygtighed samt virksomhedsetik , vi har over 190.000 dedikerede medarbejdere, der betjener vores kunder på seks kontinenter. Sammen kommer vi med nye ideer samt udvikler og skaber en bedre og dristig ny fremtid.

Forward-Looking Statements
The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov . We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye